Get the Stockscreener App
1.05
2.94%
0.03
Affimed N V Stock (AFMD) Latest News
Short Interest in Affimed (NASDAQ:AFMD) Declines By 12.3% - Defense World
Affimed (NASDAQ:AFMD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why - Defense World
Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD) - Defense World
Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest - Defense World
HC Wainwright Issues Positive Forecast for Affimed Earnings - Defense World
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks
Affimed Reports Positive Clinical Update on - GlobeNewswire
Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan
Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial - MSN
Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - Defense World
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN
Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page
Affimed to Host Investor Conference Call Highlighting - GlobeNewswire
Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan
Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - StockTitan
FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy - Yahoo Finance
Affimed Announces Acimtamig and AlloNK® Combination Granted - GlobeNewswire
Affimed's Cancer Therapy Wins FDA RMAT Status After Striking 83% Response Rate in Lymphoma Trial - StockTitan
Affimed Q3 2024 Earnings Preview - MSN
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey
10 Best German Stocks To Buy Now - Insider Monkey
Affimed's (AFMD) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Stifel Nicolaus Lowers Affimed (NASDAQ:AFMD) Price Target to $4.00 - Defense World
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat
Earnings call: Affimed reports promising results and strategic focus - Investing.com
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... By GuruFocus - Investing.com Canada
Affimed Reports Q3 2024 Financial Results and Updates - TipRanks
Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle
Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada
Affimed Faces Growing Losses Amid Financial Struggles - TipRanks
Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):